Silence Starts Phase Ib/IIa Trial of Cancer Drug as It Looks to Balance Pipeline | GenomeWeb

Silence Therapeutics this week announced that it has begun dosing patients in a phase Ib/IIa clinical trial of its cancer treatment Atu027 in combination with chemotherapy after having identified the drug’s maximum tolerated dose in a phase I study last year.

Also this week, Silence reported its 2012 financial results, posting a sharp increase in its operating loss due to a roughly £20.1 million ($30.2 million) impairment charge. Meanwhile, the company continues to weigh its options for its other pipeline programs in order to lower its dependence on Atu027.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.